Detalhe da pesquisa
1.
Synergy between imputed genetic pathway and clinical information for predicting recurrence in early stage non-small cell lung cancer.
J Biomed Inform;
144: 104424, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37352900
2.
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
BMC Cancer;
22(1): 732, 2022 Jul 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35790916
3.
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data.
BMC Cancer;
21(1): 977, 2021 Aug 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34465283
4.
Small-Cell Lung Cancer Long-Term Survivor Patients: How to Find a Needle in a Haystack?
Int J Mol Sci;
22(24)2021 Dec 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34948300
5.
Lung cancer in Spanish women: The WORLD07 project.
Eur J Cancer Care (Engl);
28(1): e12941, 2019 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30277293
6.
Pembrolizumab for the treatment of non-small-cell lung cancer.
N Engl J Med;
372(21): 2018-28, 2015 May 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25891174
7.
Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07.
Cancer Invest;
35(5): 358-365, 2017 May 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28350480
8.
Transbronchial and transesophageal fine-needle aspiration using a single ultrasound bronchoscope in the diagnosis of locoregional recurrence of surgically-treated lung cancer.
BMC Pulm Med;
17(1): 46, 2017 02 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28241873
9.
SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.
Support Care Cancer;
24(1): 499-507, 2016 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26431960
10.
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.
Future Oncol;
11(3): 421-9, 2015.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25675123
11.
HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer.
Lung Cancer;
189: 107502, 2024 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38359742
12.
Difficulties on the access to innovative targeted therapies for lung cancer in Spain.
Clin Transl Oncol;
26(3): 597-612, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37651020
13.
Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry.
Clin Transl Oncol;
2024 Jun 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38862862
14.
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.
J Clin Oncol;
42(2): 192-204, 2024 Jan 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38039427
15.
Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients.
Arch Bronconeumol;
60(2): 88-94, 2024 Feb.
Artigo
em Inglês, Espanhol
| MEDLINE
| ID: mdl-38160163
16.
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry.
Lung Cancer;
190: 107513, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38432027
17.
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer.
Clin Cancer Res;
2024 Apr 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38630755
18.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol;
13(3): 239-46, 2012 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22285168
19.
Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C.
Front Oncol;
13: 1239000, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37916173
20.
Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?
Explor Target Antitumor Ther;
4(6): 1182-1187, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38213544